News
News
- Paratek Pharmaceuticals Announces Second Quarter 2020 Total Revenue of $9.3 Million including NUZYRA® (omadacycline) Net Revenue of $8.1 Million
08/10/2020 / 13:30 - GlobeNewswire - ASLAN Pharmaceuticals to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference 2020
08/07/2020 / 09:00 - GlobeNewswire - Athenex, Inc. Reports Second Quarter Ended June 30, 2020 Financial Results and Provides Corporate Update
08/06/2020 / 13:00 - GlobeNewswire - Paratek Pharmaceuticals to Present at Two August 2020 Healthcare Conferences
08/05/2020 / 22:01 - GlobeNewswire - Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
08/03/2020 / 22:05 - GlobeNewswire - ASLAN Pharmaceuticals Appoints Kenneth Kobayashi, MD, as Chief Medical Officer
08/03/2020 / 09:17 - GlobeNewswire - Paratek Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 10, 2020
07/28/2020 / 22:01 - GlobeNewswire - ASLAN Pharmaceuticals Announces the Move of its Primary Listing to Nasdaq and Delisting From Taipei Exchange
07/17/2020 / 12:08 - GlobeNewswire - ASLAN Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
07/13/2020 / 14:06 - GlobeNewswire - Paratek Pharmaceuticals Announces Change to Time of 2020 Annual Meeting of Stockholders
05/29/2020 / 14:30 - GlobeNewswire
Real-time